CN105903086A - Central venous catheter capable of preventing thrombus - Google Patents
Central venous catheter capable of preventing thrombus Download PDFInfo
- Publication number
- CN105903086A CN105903086A CN201610399962.8A CN201610399962A CN105903086A CN 105903086 A CN105903086 A CN 105903086A CN 201610399962 A CN201610399962 A CN 201610399962A CN 105903086 A CN105903086 A CN 105903086A
- Authority
- CN
- China
- Prior art keywords
- medicine
- central venous
- venous catheter
- tissue factor
- medication coat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 77
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims abstract description 13
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims abstract description 13
- 102000002262 Thromboplastin Human genes 0.000 claims abstract description 8
- 108010000499 Thromboplastin Proteins 0.000 claims abstract description 8
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 claims abstract description 8
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims abstract 2
- 229940079593 drug Drugs 0.000 claims description 39
- 239000003937 drug carrier Substances 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 239000011247 coating layer Substances 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000036828 Device occlusion Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a central venous catheter capable of preventing thrombus. The central venous catheter comprises a central venous catheter body and medical coating layers coating the walls of the catheter. Each medicine coating layer comprises medicine and a medicine carrier, wherein the medicine is tissue factor pathway inhibitor TFPI-1 or TFPI-2, and the mass ratio of the medicine to the medicine carrier is 1:(4-7.9). Both the inner wall and the outer wall of the catheter body are coated with the medicine coating layers. The thickness of the medicine coating layers is 20-40 micrometers. The central venous catheter has the advantages that the tissue factor pathway inhibitor is applied to the central venous catheter body, so that thrombogenesis and bacterial infection in the central venous catheter body are effectively prevented, the pain and burden of a patient are reduced, the workload of medical staff is reduced, and working efficiency is improved. The tissue factor pathway inhibitor is tissue factor physiological inhibitor, has good blood compatibility and tissue compatibility compared with other medicine, has no toxic or side effect and has few influences on the human body.
Description
Technical field
The present invention relates to medical venous duct, particularly to a kind of can the central venous catheter of pre-preventing thrombosis.
Background technology
Central venous catheter is a kind of common medical apparatus and instruments, and it inserts the vein of patient by puncture technique, such as quiet in neck
Arteries and veins, infuses to patient.The clinical much client need central venous catheter that peripheral blood vessel condition is very poor is as vein
Transfusion path, owing to its misery is little, the advantage of indwelling time length is promoted clinically, but it is a series of also to put Guan Houhui generation
Send out disease, particularly conduit dependency thrombosis, not only add misery and financial burden to patient, bring tired to medical worker's work
Difficulty, once thrombus breaks loose causes pulmonary infarction even threat to life.
The main method preventing thromboembolism at present clinically is employing heparin in sealing after dialysis, and heparin in sealing repeatedly is not
But increase patient medical expense, and the heparin in pipe also can constantly be discharged in blood, increase bleeding risk.Locate clinically
Reason thromboembolism and the method for catheter blockage caused because fibrin sheath parcel are usually and repeatedly use after capsid is formed
Red cell morphology in urine, but poor effect.Red cell morphology in urine repeatedly there is drawbacks in that 1, somewhat expensive, and patient is difficult to bear, 2,
Urokinase has the complication of systemic bleeding, and life-threatening is exactly Complications of Cerebral Hemorrhage.Next to that use fibrin sheath to tear
Fibrin sheath is pulled out by de-art, but this operating difficulty is big, and general hospital is difficult to carry out, and operation needs to carry out under radiography,
Somewhat expensive.
So be badly in need of clinically a kind of can effectively in prevention center venous duct the new catheter of thrombosis to come elongation center quiet
The indwelling time of arteries and veins conduit, reduces misery and burden for patient, improves the work efficiency of medical personnel.
Summary of the invention
It is an object of the invention to overcome above-mentioned weak point and provide a kind of can the central venous catheter of pre-preventing thrombosis.Catheter wall
On have medication coat, medication coat is tissue factor pathway inhibitor, and tissue factor pathway inhibitor is the physiology of tissue factor
Inhibitor, compared with other drug, has good blood compatibility and histocompatibility.
The present invention adopts the following technical scheme that.
Can the central venous catheter of pre-preventing thrombosis, including central venous catheter and the medication coat that is coated on catheter wall, institute
Stating medication coat and include that medicine and pharmaceutical carrier, described medicine are tissue factor pathway inhibitor, described tissue factor approach presses down
Thing processed is TFPI-1 or TFPI-2, and medicine is 1:4～7.9 with the mass ratio of pharmaceutical carrier.Described medication coat thickness be 20～
40 microns.
Described medicine is TFPI-1.
Described medicine is TFPI-2.
Medication coat is all had on the wall of described conduit and outer wall.
The wall of described conduit has medication coat.
Described medication coat, medicine is 1:4 or 1:7 with the mass ratio of pharmaceutical carrier.
Described medication coat thickness is 25 microns or 35 microns.
It is an advantage of the current invention that:
Tissue factor is the startup factor of exogenous cruor pathway.Under physiological conditions, the hemocyte directly contacted with blood circulation
With the endotheliocyte not expression tissue factor, when vascular endothelial cell is impaired, tissue factor exposes thus activates platelet, promotes
Adhere to each other between platelet and gathering causes Intravascular Thrombus to be formed.
Tissue factor pathway inhibitor is discharged as the medicine of central venous catheter medication coat in conduit, not only may be used
With thrombosis in prevention conduit, and the use of anticoagulant can be reduced, thus reduce incidence rate and the treatment cost of bleeding episode
With, and owing to only discharging in conduit, functioning efficiency is high, and little on the impact of whole body blood coagulation system.
1. tissue factor pathway inhibitor is applied in central venous catheter, sending out of thrombosis in venous patient conduit can be made
Raw rate reduces.
2. the incidence rate that can make patient's bleeding episode reduces.
3. tissue factor pathway inhibitor is the physiological inhibitor of tissue factor, compared with other drug, has good
Blood compatibility and histocompatibility, have no side effect, little effect on the human body.
Accompanying drawing explanation
Fig. 1 is the embodiment of the present invention four support and medication coat structure sectional view；
Fig. 2 is the embodiment of the present invention five support and medication coat structure sectional view.
Detailed description of the invention
In conjunction with the embodiments and accompanying drawing, the present invention is further illustrated.
Can the central venous catheter of pre-preventing thrombosis, including central venous catheter and the medication coat that is coated on catheter wall, institute
State medication coat and include that medicine and pharmaceutical carrier, described medicine are tissue factor pathway inhibitor, its English entitled tissue
Factor pathway inhibitor, described tissue factor pathway inhibitor is TFPI-1 or TFPI-2, and medicine carries with medicine
The mass ratio of body is 1:4～7.9.Described medication coat thickness is 20～40 microns.
Described medicine is TFPI-1.
Described medicine is TFPI-2.
Medication coat is all had on the wall of described central venous catheter and outer wall.
The wall of described conduit has medication coat.
Described medication coat, medicine is 1:4 or 1:7 with the mass ratio of pharmaceutical carrier.
Described medication coat thickness is 25 microns or 35 microns.
Described pharmaceutical carrier is prior art.Conventional pharmaceutical carrier be dichloromethane, ethyl acetate, acrylic acid methyl ester.,
Copolymer containing methyl methacrylate monomer, polylactic acid, polyglycolic acid, poly-racemic lactic acid, polylactide-co-glycolide gather
One or more combination in compound, Phosphorylcholine, poly-aethylis carbamas, inorganic microporous aluminium sesquioxide, cellulose
Thing.
Medication coat embodiment about the present invention is as follows.
Embodiment one: in medication coat, described medicine, for TFPI-1, described pharmaceutical carrier is dichloromethane, medicine and medicine
The mass ratio of thing carrier is 1:4；Medication coat thickness is 25 microns.
Embodiment two: in medication coat, described medicine, for TFPI-2, described pharmaceutical carrier is polylactic acid, medicine and pharmaceutical carrier
Mass ratio be 1:7；Medication coat thickness is 35 microns.
Embodiment three: in medication coat, described medicine, for TFPI-1, described pharmaceutical carrier is ethyl acetate, medicine and medicine
The mass ratio of thing carrier is 1:5.5；Medication coat thickness is 30 microns.
As follows about the central venous catheter of the present invention and the constructive embodiment of medication coat.
Embodiment four: Fig. 1 is central venous catheter of the present invention and medication coat structure sectional view, the wall of venous duct 1
With all have medication coat 2 on outer wall.
Embodiment five: Fig. 2 is central venous catheter of the present invention and medication coat structure sectional view, the wall of venous duct 1
On have medication coat 2.
Claims (7)
1. can the central venous catheter of pre-preventing thrombosis, including conduit and the medication coat that is coated on catheter wall, described medicine
Coating includes medicine and pharmaceutical carrier, it is characterized in that: described medicine is tissue factor pathway inhibitor, described tissue factor approach
Mortifier is TFPI-1 or TFPI-2, and medicine is 1:4～7.9 with the mass ratio of pharmaceutical carrier, and described medication coat thickness is 20
～40 microns.
2. according to described in claim 1 can the central venous catheter of pre-preventing thrombosis, it is characterised in that: described medicine is TFPI-
1。
3. according to described in claim 1 can the central venous catheter of pre-preventing thrombosis, it is characterised in that: described medicine is TFPI-
2。
4. according to described in claim 1 can the central venous catheter of pre-preventing thrombosis, it is characterised in that: described venous duct
Medication coat is all had on wall and outer wall.
5. according to described in claim 1 can the central venous catheter of pre-preventing thrombosis, it is characterised in that: described venous duct
Wall has medication coat.
6. according to described in claim 1 can the central venous catheter of pre-preventing thrombosis, it is characterized in that: described medication coat, medicine
It is 1:4 or 1:7 with the mass ratio of pharmaceutical carrier.
7. according to described in claim 1 can the central venous catheter of pre-preventing thrombosis, it is characterized in that: described medication coat thickness is
25 microns or 35 microns.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610399962.8A CN105903086A (en) | 2016-06-08 | 2016-06-08 | Central venous catheter capable of preventing thrombus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610399962.8A CN105903086A (en) | 2016-06-08 | 2016-06-08 | Central venous catheter capable of preventing thrombus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105903086A true CN105903086A (en) | 2016-08-31 |
Family
ID=56750484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610399962.8A Pending CN105903086A (en) | 2016-06-08 | 2016-06-08 | Central venous catheter capable of preventing thrombus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105903086A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113144376A (en) * | 2021-04-16 | 2021-07-23 | 上海市胸科医院 | Nano double-resistance deep venous catheter |
| CN113144375A (en) * | 2021-04-16 | 2021-07-23 | 上海市胸科医院 | Anti-wall-sticking double-resistance nano hemodialysis catheter |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101185778A (en) * | 2007-12-19 | 2008-05-28 | 上海赢生医疗科技有限公司 | Novel medicinal bracket for treating blood vessel disease |
| WO2010084199A1 (en) * | 2009-01-26 | 2010-07-29 | Academisch Medisch Centrum | Drug delivery system for use in the treatment of vascular and vessel-related pathologies |
| CN204798584U (en) * | 2015-05-13 | 2015-11-25 | 深圳市顺美医疗科技有限公司 | Prevent thrombus central venous catheter |
| CN105228664A (en) * | 2013-03-15 | 2016-01-06 | 雅培心血管系统有限公司 | For the tissue adherence coating of medicinal balloon |
-
2016
- 2016-06-08 CN CN201610399962.8A patent/CN105903086A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101185778A (en) * | 2007-12-19 | 2008-05-28 | 上海赢生医疗科技有限公司 | Novel medicinal bracket for treating blood vessel disease |
| WO2010084199A1 (en) * | 2009-01-26 | 2010-07-29 | Academisch Medisch Centrum | Drug delivery system for use in the treatment of vascular and vessel-related pathologies |
| CN105228664A (en) * | 2013-03-15 | 2016-01-06 | 雅培心血管系统有限公司 | For the tissue adherence coating of medicinal balloon |
| CN204798584U (en) * | 2015-05-13 | 2015-11-25 | 深圳市顺美医疗科技有限公司 | Prevent thrombus central venous catheter |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113144376A (en) * | 2021-04-16 | 2021-07-23 | 上海市胸科医院 | Nano double-resistance deep venous catheter |
| CN113144375A (en) * | 2021-04-16 | 2021-07-23 | 上海市胸科医院 | Anti-wall-sticking double-resistance nano hemodialysis catheter |
| CN113144376B (en) * | 2021-04-16 | 2024-03-29 | 上海市胸科医院 | Nanometer double-resistance deep vein catheter |
| CN113144375B (en) * | 2021-04-16 | 2024-04-02 | 上海市胸科医院 | Wall-sticking-preventing double-resistance nano hemodialysis catheter |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BERNHARD et al. | Temporary left ventricular bypass: Factors affecting patient survival | |
| Borger et al. | Multiple arterial grafts: radial versus right internal thoracic arteries | |
| Borger et al. | Decreased cerebral emboli during distal aortic arch cannulation: a randomized clinical trial | |
| den Uil et al. | Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention | |
| JP2013078575A (en) | Catheter with external flow channel | |
| CN110353752A (en) | Heart coronaries Venous Occlusion device | |
| CN203898496U (en) | Abdominal aorta stent | |
| CN105903086A (en) | Central venous catheter capable of preventing thrombus | |
| Oh et al. | Radial artery cannulation | |
| Lee et al. | Massive hemothorax immediately after removal of central venous catheter-A case report | |
| Jin et al. | Research on comprehensive analysis of patient comfort and complication rate using haemodialysis indwelling needles in AVF puncture in haemodialysis treatment | |
| Kanterman et al. | Graft-to-vein fistulas associated with polytetrafluoroethylene dialysis grafts: diagnosis and clinical significance | |
| Massi et al. | Myocardial infarction and rupture after bronchial artery embolization | |
| CN212593463U (en) | Medical catheter | |
| Marinelli et al. | The heart is not a pump | |
| KOPMAN et al. | Intraoperative monitoring of femoral artery pressure during replacement of aneurysm of descending thoracic aorta | |
| McCulloch | Use of the Impella 2.5 in high-risk percutaneous coronary intervention | |
| CN111790050A (en) | Medical catheter structure for external bridging and application thereof | |
| RU2649572C1 (en) | Method of treatment of patients with acute myocardial infarction with massive thrombosis of the infarct-related coronary artery | |
| Zhu et al. | Femoral artery variation was found during VA ECMO catheterization: a case report | |
| Heller et al. | Safety of intensivist-led bedside decannulation of internal jugular bi-caval dual-lumen veno-venous extracorporeal membrane oxygenation cannulas and report of technique | |
| Goldich | Getting in sync with intra-aortic balloon pump therapy | |
| Sogawa et al. | Thrombus on the intraluminal felt strip: a possible cause of postoperative stroke | |
| Wang et al. | Perioperative coagulation management during left ventricular assist device implantation surgery for end-stage heart failure: four cases and literature review | |
| Dalibon et al. | Probable allergic reaction to cyclosporin and early formation of thrombi on a pulmonary artery catheter: two unusual complications during bilateral lung transplantation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160831 |
|
| WD01 | Invention patent application deemed withdrawn after publication |